Gebhart, G <br/><br/>
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Apr 2016 
 - 619-24 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdv577  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Ado-Trastuzumab Emtansine<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Breast Neoplasms--diagnostic imaging<br/>Female<br/>Fluorodeoxyglucose F18--administration & dosage<br/>Humans<br/>In Situ Hybridization, Fluorescence<br/>Maytansine--administration & dosage<br/>Middle Aged<br/>Positron-Emission Tomography<br/>Receptor, ErbB-2--genetics<br/>Trastuzumab<br/>Treatment Outcome